TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27512321

Group type: EXPERIMENTAL
Intervention: Yoga program for 12 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 81
Study: 24847496

Group type: EXPERIMENTAL
Intervention: Toothbrush 1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Toothbrush 2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Toothbrush 3
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Toothbrush 4
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dental Floss (used after 2 weeks)
Number of subjects: 60
Study: 22244150

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole prophylaxis (before 2008)
Number of subjects: 10474

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin prophylaxis (after 2008)
Number of subjects: 10474

Group type: EXPERIMENTAL
Intervention: Overall PNB procedure
Number of subjects: 10474
Study: 19934787

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV, Fluzone, sanofi pasteur; N = 915)
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Placebo (N = 460)
Number of subjects: 1375
Study: 17359405

Group type: EXPERIMENTAL
Intervention: Midazolam/Fentanyl (M/F)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Midazolam/Ketamine (M/K)
Number of subjects: 57
Study: 15660048

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12407781

Group type: EXPERIMENTAL
Intervention: Perindopril/Indapamide (2 mg/0.625 mg)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 471
Study: 10660864

Group type: EXPERIMENTAL
Intervention: Carbohydrate (C, n = 8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Placebo (P, n = 8)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (N, n = 6)
Number of subjects: 22
Study: 7799021

Group type: EXPERIMENTAL
Intervention: Oral etoposide phosphate (escalated from 50 mg/m2/d to 220 mg/m2/d for 5 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous etoposide phosphate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral etoposide phosphate
Number of subjects: 40
Study: 1821833

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7044798

Group type: EXPERIMENTAL
Intervention: Benoxaprofen (600 mg once a day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Indomethacin (25 mg t.i.d.)
Number of subjects: 35
Study: 30609441

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg daily for 2 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amlodipine discontinuation
Number of subjects: 40
Study: 29132339

Group type: EXPERIMENTAL
Intervention: 3-day Cetrotide sc injection (0.25 mg/day) started on Day-0
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no Cetrotide therapy)
Number of subjects: 48
Study: 27998859

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion at 5 mg·kg‐1·h‐1
Number of subjects: 108

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion
Number of subjects: 108

Group type: COMPARATOR
Intervention: Magnesium sulphate infusion and Saline (control group)
Number of subjects: 108
Study: 24468007

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL) vs Dihydroartemisinin-piperaquine (DP)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Temperature ≥38.0°C vs <37.0°C
Number of subjects: 202

Group type: COMPARATOR
Intervention: Parasite density >20,000/μL vs <4,000/μL
Number of subjects: 202
Study: 23000025

Group type: EXPERIMENTAL
Intervention: DASH diet plus weight management
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: DASH diet alone
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual Diet Controls
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: DASH diet adherence
Number of subjects: 144
Study: 19617586

Group type: EXPERIMENTAL
Intervention: History of early correction for myopia as a child or young adult
Number of subjects: 101

Group type: COMPARATOR
Intervention: No early correction for myopia
Number of subjects: 101
Study: 18283926

Group type: EXPERIMENTAL
Intervention: Indoor environment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outdoor environment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptual matching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blindwalking
Number of subjects: 0
Study: 16435069

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12218276

Group type: EXPERIMENTAL
Intervention: Fluoridated topical gel (12500 ppm F, partly as NaF, Olafluor and Dectafluor, pH 4.5) + fluoridated toothpaste (1450 ppm F as NaF)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fluoridated toothpaste (1450 ppm F as NaF) alone
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fluoridated topical gel + fluoridated toothpaste
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fluoridated toothpaste alone
Number of subjects: 26
Study: 10800491

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy including platin-compounds (cisplatin, carboplatin) and podophyllotoxins (etoposide, teniposide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platin-containing regimens with new agents (gemcitabine, taxenes, navelbine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topotecan and paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative and preirradiatory chemotherapy
Number of subjects: 0
Study: 7540812

Group type: EXPERIMENTAL
Intervention: 7.2% hypertonic saline/6% hetastarch
Number of subjects: 26

Group type: COMPARATOR
Intervention: 6% hetastarch (control)
Number of subjects: 26
Study: 2354297

Group type: EXPERIMENTAL
Intervention: Regular surveillance using an activities of daily living questionnaire administered by volunteers
Number of subjects: 539

Group type: COMPARATOR
Intervention: Control group (no regular surveillance)
Number of subjects: 539
Study: 403421

Group type: EXPERIMENTAL
Intervention: Intravenous Actovegin
Number of subjects: 114

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 114
Study: 30387273

Group type: EXPERIMENTAL
Intervention: Responsive yes/no questions
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Unsuccessful redirectives
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Fluency and connectedness
Number of subjects: 249
Study: 28263398

Group type: EXPERIMENTAL
Intervention: Inner Resources for Stress mindfulness meditation and mantra training (IR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Psychoeducation and telephone support (PTS)
Number of subjects: 31
Study: 26301648

Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 31048
Study: 23333007

Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 22308557

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (200 U or 300 U)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (second injection)
Number of subjects: 85

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 85
Study: 19293358

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered every week or every other week, titrated to maintain hemoglobin within +/-1.0 g/dL of baseline values, with a target range of 9.0 - 12.0 g/dL for up to 24 weeks.
Number of subjects: 73
Study: 17357126

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 14750292

Group type: EXPERIMENTAL
Intervention: Student-delivered method for obtaining parental consent
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Mail method for obtaining parental consent
Number of subjects: 1058
Study: 11260580

Group type: EXPERIMENTAL
Intervention: Individualized Scheduled Toileting (IST) program
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no IST program)
Number of subjects: 118
Study: 10437265

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 8177626

Group type: EXPERIMENTAL
Intervention: DTaP
Number of subjects: 80

Group type: COMPARATOR
Intervention: DTwP
Number of subjects: 80
Study: 3300565

Group type: COMPARATOR
Intervention: Etretinate therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: PUVA treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined treatment (PUVA + etretinate)
Number of subjects: 30
Study: 29464342

Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 101

Group type: COMPARATOR
Intervention: 18-month DAPT
Number of subjects: 101
Study: 27748721

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 229

Group type: COMPARATOR
Intervention: 5-fluorouracil
Number of subjects: 229
Study: 24814973

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation combined with tracheal gas insufflation (HFO-TGI) for 8 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation combined with tracheal gas insufflation (HFO-TGI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation with recruitment maneuvers (RMs) for 8 hours
Number of subjects: 12
Study: 22730343

Group type: EXPERIMENTAL
Intervention: MTX + etanercept or MTX + hydroxychloroquine + sulfasalazine triple therapy
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Initial treatment with MTX with step-up to MTX + etanercept or to triple therapy if disease was still active at 24 weeks
Number of subjects: 412
Study: 19781964

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine via pain-control infusion pumps (PCIP) at a flow rate of 2 mL/h for 48 h
Number of subjects: 92

Group type: COMPARATOR
Intervention: 0.9% normal saline via pain-control infusion pumps (PCIP) at a flow rate of 2 mL/h for 48 h
Number of subjects: 92
Study: 18431444

Group type: EXPERIMENTAL
Intervention: 4-site ID regimen (0.1 ml at 4 ID sites on day 0, 0.1 ml ID at 2 sites on day 7, and at one site on days 28 and 90)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: 2-site ID regimen
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: 8-site ID regimen (0.05 ml per ID site)
Number of subjects: 254

Group type: COMPARATOR
Intervention: 5-dose intramuscular regimen
Number of subjects: 254
Study: 16483029

Group type: EXPERIMENTAL
Intervention: Intracavernosal injection of papaverine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral sildenafil
Number of subjects: 50
Study: 12454842

Group type: EXPERIMENTAL
Intervention: Genotype A
Number of subjects: 258

Group type: COMPARATOR
Intervention: Genotype F
Number of subjects: 258
Study: 10508813

Group type: EXPERIMENTAL
Intervention: Spiros dry powder inhaler (90- and 270-microgram albuterol base)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ventolin metered dose inhaler (90- and 270-microgram albuterol base)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Spiros dry powder inhaler and Ventolin metered dose inhaler
Number of subjects: 24
Study: 7582300

Group type: EXPERIMENTAL
Intervention: Secretory leukocyte protease inhibitor (SLPI)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight antiproteases
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA) for SLPI
Number of subjects: 23
Study: 2029994

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 6272429

Group type: EXPERIMENTAL
Intervention: Symptomatic climacteric women
Number of subjects: 33

Group type: COMPARATOR
Intervention: Asymptomatic postmenopausal women
Number of subjects: 33
Study: 29752008

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU weekly for 9 weeks)
Number of subjects: 253
Study: 27440177

Group type: EXPERIMENTAL
Intervention: Hippotherapy (30 minutes once weekly for 12 consecutive weeks)
Number of subjects: 14
Study: 25916959

Group type: EXPERIMENTAL
Intervention: Standard settings (pulse width 210 μs, frequency 14 Hz)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Group 4 (pulse width 90 μs, frequency 14 Hz)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Groups 2-5 (pulse width and/or frequency halved or doubled)
Number of subjects: 11
Study: 24619335

Group type: EXPERIMENTAL
Intervention: 2-h VR simulator training in the laparoscopic sigmoid colectomy module (study group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 14
Study: 21533812

Group type: EXPERIMENTAL
Intervention: AC/CAF chemotherapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: CMF chemotherapy
Number of subjects: 54
Study: 19533067

Group type: EXPERIMENTAL
Intervention: Fast track concept in vascular surgery; introduced on May 1st 2008 with special adjustments.
Number of subjects: 0
Study: 17961837

Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus block combined with PCA
Number of subjects: 34

Group type: COMPARATOR
Intervention: PCA only
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus block
Number of subjects: 34
Study: 15037058

Group type: EXPERIMENTAL
Intervention: HIV-associated dementia (HAD)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nondemented persons with HIV infection (HIV+)
Number of subjects: 21
Study: 11525524

Group type: EXPERIMENTAL
Intervention: In-home parenting instruction
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (no in-home parenting instruction)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Overall intervention (intensive home visitation component)
Number of subjects: 171
Study: 9716035

Group type: EXPERIMENTAL
Intervention: PVI 5-FU-based chemotherapy
Number of subjects: 8
Study: 2663153

Group type: EXPERIMENTAL
Intervention: Conventional formulation of trazodone, 100 mg for 1 week, followed by 200 mg or less for 3 weeks.
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Controlled-release formulation of trazodone, 100 mg for 1 week, followed by 200 mg or less for 3 weeks.
Number of subjects: 166

Group type: COMPARATOR
Intervention: Conventional formulation of trazodone
Number of subjects: 166

Group type: COMPARATOR
Intervention: Controlled-release formulation of trazodone
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 166
Study: 31552779

Group type: EXPERIMENTAL
Intervention: LPS-induced TNF-α
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: LPS-induced IL-6
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: LPS-induced TNF-α + IL-6
Number of subjects: 117

Group type: COMPARATOR
Intervention: Circulating biomarkers
Number of subjects: 117

Group type: COMPARATOR
Intervention: Entire sample
Number of subjects: 117
Study: 30468901

Group type: EXPERIMENTAL
Intervention: Knee flexion position at 60° for 24 hours after surgery without tourniquet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tourniquet use with the same flexion position as Group A
Number of subjects: 100
Study: 26719401

Group type: EXPERIMENTAL
Intervention: CABG + CRT
Number of subjects: 178

Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 178
Study: 25496446

Group type: EXPERIMENTAL
Intervention: Acupuncture Group (AG) - electroacupuncture at sub-specific points (Shaoyang meridians, Luxi (TE19), San Yangluo (TE8), Xi Yangguan (GB33))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham Acupuncture Group (SAG) - non-acupoints stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Migraine Group (MG) - no treatment
Number of subjects: 30
Study: 23157714

Group type: EXPERIMENTAL
Intervention: Trunk Release Maneuver (TRM)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard High Fowler's position (Control)
Number of subjects: 117
Study: 20535581

Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Capsule (XFZY)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Shengmai Capsule (SM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 18272546

Group type: EXPERIMENTAL
Intervention: MMX mesalazine 2.4 g/day (once-daily dosing)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: MMX mesalazine 2.4 g/day (twice-daily dosing)
Number of subjects: 174
Study: 14999298

Group type: EXPERIMENTAL
Intervention: DAC-7 (daunorubicin 60 mg/m2/day, days 1-3; cytarabine 200 mg/m2/day, days 1-7; cladribine 5 mg/m2/day, days 1-5)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: DAC-7
Number of subjects: 400

Group type: COMPARATOR
Intervention: DA-7 (without cladribine)
Number of subjects: 400

Group type: COMPARATOR
Intervention: DA-7
Number of subjects: 400
Study: 11429349

Group type: EXPERIMENTAL
Intervention: Propofol with EDTA
Number of subjects: 69

Group type: COMPARATOR
Intervention: Propofol without EDTA
Number of subjects: 69
Study: 9511845

Group type: EXPERIMENTAL
Intervention: Preference group (subjects choose their treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized group (random allocation to treatment)
Number of subjects: 0
Study: 8276667

Group type: EXPERIMENTAL
Intervention: Intracavitary application with total reference air kerma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reference isodose surface
Number of subjects: 0
Study: 2848053

Group type: EXPERIMENTAL
Intervention: CORT (500 mg bolus injection within 5 s of the start of surgery)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FENT (50-100 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CORT (500 mg bolus injection) + FENT (50-100 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No CORT, No FENT (Group I)
Number of subjects: 30
Study: 30727856

Group type: EXPERIMENTAL
Intervention: Thrombectomy in core-too-large patients
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Thrombectomy in NIHSS 6 to 9 group
Number of subjects: 71
Study: 29076318

Group type: EXPERIMENTAL
Intervention: PDRN (5.625 mg, 3 mL, intramuscular 5 days a week and perilesional 2 days a week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% normal saline (3 mL)
Number of subjects: 20
Study: 26421852

Group type: EXPERIMENTAL
Intervention: Interactive e-learning module on appropriate imaging referrals for pulmonary embolism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive e-learning module on cervical spine trauma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static versions of CDRs
Number of subjects: 0
Study: 22831853

Group type: EXPERIMENTAL
Intervention: TOCAS 0.4 mg plus SOLI 6 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TOCAS 0.4 mg plus SOLI 9 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22333618

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) treatment with PBMC culture
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Post-thymectomy PBMC
Number of subjects: 58

Group type: COMPARATOR
Intervention: Purified protein derivative (PPD) test
Number of subjects: 58
Study: 19922649

Group type: EXPERIMENTAL
Intervention: Digestive Advantage Gas Defense Formula (GanedenBC30 Bacillus coagulans GBI‐30, 6086)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 16803740

Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST) delivered by Master's trained social workers in a primary care setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15000548

Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rehearsal
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (freely chosen strategy)
Number of subjects: 120
Study: 11103184

Group type: EXPERIMENTAL
Intervention: 4% gelatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6% low‐molecular weight (LMW) hydroxyethyl starch (HES)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6% medium‐molecular weight (MMW) HES
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (4% gelatin, 6% LMW HES, 6% MMW HES)
Number of subjects: 60
Study: 9350665

Group type: EXPERIMENTAL
Intervention: Blood side standard method for eKt/V
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dialysate side measurements
Number of subjects: 35

Group type: COMPARATOR
Intervention: Single-sample intradialysis method
Number of subjects: 35

Group type: COMPARATOR
Intervention: Multiple-sample intradialysis method
Number of subjects: 35

Group type: COMPARATOR
Intervention: Rate method
Number of subjects: 35

Group type: COMPARATOR
Intervention: All four alternative methods
Number of subjects: 35
Study: 8349933

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized cat extract (total dose approximately 4,500,000 allergy units)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized cat extract
Number of subjects: 41
Study: 3954442

Group type: EXPERIMENTAL
Intervention: Spinal bracing using a rigid supporting jacket
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Change from sitting to supine position
Number of subjects: 40
Study: 31927499

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT) for 3 weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Number of subjects: 54
Study: 30517724

Group type: EXPERIMENTAL
Intervention: Oral vitamin A supplementation (VAS) of 10,000 IU weekly until 6 mo postpartum
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 27550645

Group type: EXPERIMENTAL
Intervention: Polycystic kidney disease cohort
Number of subjects: 4346

Group type: COMPARATOR
Intervention: Control non-policystic kidney disease cohort
Number of subjects: 4346
Study: 24882907

Group type: EXPERIMENTAL
Intervention: Prompt intervention (sleep education program)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 152
Study: 21881597

Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50